Viltolarsen
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.
Journal: Biomolecules
Published: April 26, 2026
Treatment advances for Duchenne muscular dystrophy.
Journal: Current opinion in pediatrics
Published: April 01, 2026
Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.
Journal: Frontiers in pharmacology
Published: October 07, 2025
The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022.
Journal: Pharmaceutical medicine
Published: September 09, 2025
Evolution and Breakthroughs in Exon Skipping and Splice Modulation: From Inception to Clinical Success.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
Exon-Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis.
Journal: Journal of comparative effectiveness research
Published: July 18, 2025
Systematic analysis of the adverse effects of used clinical antisense oligonucleotide drugs in DMD patients based on the FAERS database.
Journal: European journal of clinical pharmacology
Published: April 20, 2025
Last Updated: 09/26/2026